Stockscreener 앱 받기
177.89
0.46%
-0.82
시간 외 거래:
177.89
Astrazeneca Plc 주식(AZN)의 최신 뉴스
ASTRAZENECA : Gets a Buy rating from Jefferies - marketscreener.com
AstraZeneca says AI is raising its odds where most drugs fail - thestreet.com
EHA26: AstraZeneca battles Roche in untreated follicular lymphoma - Clinical Trials Arena
This Aggressive Prostate Cancer Finally Has Targeted Treatment — AstraZeneca Wins FDA Nod - Benzinga
AstraZeneca slips Monday, underperforms market - MarketWatch
AstraZeneca's Truqap Wins FDA Nod for Prostate Cancer Indication - Yahoo Finance
US approves AstraZeneca (NYSE: AZN) Truqap combo for PTEN-deficient metastatic prostate cancer - Stock Titan
AstraZeneca PLC (AZN) Stock Analysis: Exploring a 25.59% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
FDA Grants Priority Review to AstraZeneca’s Ultomiris for Rare Kidney Disease Treatment (AZN) - Yahoo Finance UK
Astrazeneca secures US approval for Truqap combo in PTEN‑deficient prostate cancer - Sharecast.com
AstraZeneca's Ultomiris wins US FDA priority review in kidney disease - marketscreener.com
Astrazeneca Plc Gains US Approval For Truqap In PTEN-deficient Prostate Cancer - DirectorsTalk Interviews
TRUQAP Approval Adds Precision Prostate Cancer Upside To AstraZeneca Valuation - Yahoo Finance
AZN Stock Quote Price and Forecast - CNN
CVT Nasdaq-100 Index Portfolio's AstraZeneca PLC(AZN) Holding History - GuruFocus
AVIP Nasdaq-100 Index Portfolio's AstraZeneca PLC(AZN) Holding History - GuruFocus
AstraZeneca says Truqap combination approved in US for prostate cancer - London South East
AstraZeneca (AZN) Gains from New Diagnostic Test Approval - GuruFocus
AstraZeneca (AZN) Secures U.S. Approval for Innovative Prostate Cancer Treatment - GuruFocus
AstraZeneca Truqap Ok'd in U.S. for prostate cancer (AZN:NYSE) - Seeking Alpha
AstraZeneca : Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer - marketscreener.com
AstraZeneca PLC Stock (US6549022043): ADR inches higher on Nasdaq as pharma heavyweight stays in foc - AD HOC NEWS
AstraZeneca PLC Stock (US6549022043): Deutsche Bank sticks to Sell rating as shares edge higher - AD HOC NEWS
AstraZeneca PLC (AZN) Presents at American Diabetes Association (ADA) 86th Scientific SessionsSlideshow - Seeking Alpha
Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Jazz, AstraZeneca, Astellas: Foreign healthcare's strongest quant picks - MSN
AstraZeneca PLC Stock (US6549022043): Obesity Drug Elecoglipron Heads Into Phase 3 As Shares Climb - AD HOC NEWS
ASTRAZENECA : Deutsche Bank maintains a Sell rating - marketscreener.com
AstraZeneca | Pharmaceuticals, Vaccines, & Facts | Britannica Money - Britannica
ADA 2026: AstraZeneca To Move Fast On Obesity And Heart Pill Combinations - Citeline News & Insights
Jim Cramer on AstraZeneca: “On Track to Hit the Ambitious Long-Term Financial Targets” - Yahoo Finance
Hansa Biopharma appoints Head of Business Development from AstraZeneca - marketscreener.com
AstraZeneca advances oral GLP-1 elecoglipron into phase 3 - MSN
AstraZeneca PLC stock (US6549022043): obesity drug data and pipeline momentum keep investors alert - AD HOC NEWS
AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials - Benzinga
Functional genomics and AI drive novel target discovery at AstraZeneca - Select Science
State Street Premier Growth Equity V.I.S. Fund's AstraZeneca PLC(AZN) Holding History - GuruFocus
ASTRAZENECA : JP Morgan remains its Buy rating - marketscreener.com
ADA26: AstraZeneca unveils positive data for Phase III-ready oral GLP-1RA - Clinical Trials Arena
MitoRx Therapeutics Strengthens Leadership Team with C-Suite and Board Appointments to Support Next Phase of Growth - GlobeNewswire Inc.
AstraZeneca reprimanded over LinkedIn likes once again - Fierce Pharma
AstraZeneca Advances Obesity, Diabetes Medication Elecoglipron to Phase 3 Trial - marketscreener.com
AstraZeneca PLC (AZN) Stock Analysis: Robust Revenue Growth and a 20.73% Upside Potential - DirectorsTalk Interviews
ASTRAZENECA : Deutsche Bank reiterates its Sell rating - marketscreener.com
NYLIM VP Income Builder Portfolio's AstraZeneca PLC(AZN) Holding History - GuruFocus
BofA reiterates Buy on AstraZeneca stock, cites adjuvant trial outlook By Investing.com - Investing.com South Africa
AstraZeneca progresses elecoglipron after positive phase IIb results - London South East
Why is CAMBRIA-1 emerging as AstraZeneca’s key breast cancer catalyst? - Investing.com Nigeria
ASTRAZENECA : Jefferies remains its Buy rating - marketscreener.com
AstraZeneca Gears Up for Phase 3 Trial of Weight-loss Drug - marketscreener.com
IAMS WEALTH MANAGEMENT, LLC's AstraZeneca PLC(AZN) Holding History - GuruFocus
AstraZeneca (AZN) Advances Elecoglipron to Phase 3 Trials After Positive Results - GuruFocus
Elecoglipron cut nearly 12% of body weight in study, AstraZeneca says - AOL.com
AstraZeneca unveils data behind Phase III-bound oral GLP-1 - FirstWord Pharma
AstraZeneca’s oral GLP-1 advances to Phase III after strong trial results - Investing.com Nigeria
AstraZeneca obesity pill shows 10.5% weight loss in trial By Investing.com - Investing.com UK
AstraZeneca : Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney portfolio - marketscreener.com
AstraZeneca obesity pill helps patients lose 10.5% of body weight in trial - marketscreener.com
AstraZeneca advances weight-loss pill to take aim at obesity leaders - Financial Times
ADA 2026: AstraZeneca Advances Oral GLP-1 Elecoglipron Into Phase III After Positive Trial Data - Citeline News & Insights
AstraZeneca plc stock (GB0009895292): Oncology pipeline, obesity push and latest trial updates in fo - AD HOC NEWS
AstraZeneca hails phase 3 trial results of inhibitor Ultomiris - London South East
AstraZeneca warns it could delay Europe drug launchesFT - marketscreener.com
PRESS: AstraZeneca warns it could delay Europe drug launchesFT - London South East
0.23%
0.03%
자본화:
|
볼륨(24시간):